Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

German Measles Officially Eliminated in North, South America

April 29, 2015 4:13 pm | by Mike Stobbe, AP Medical Writer | News | Comments

Vaccines against German measles were first licensed in 1969, and were included in mass vaccination campaigns. It is now part of childhood shots. Read more...

TOPICS:

Flu Kills Millions of Birds, May Spread to Humans

April 29, 2015 1:41 pm | by Seth Augenstein, Digital Reporter | News | Comments

A strain of avian flu that has spread to chickens and turkeys in the Midwest and caused the death of millions of birds could make the jump to humans in time for next flu season, according to the U.S. Department of Agriculture and the Centers for Disease Control and Prevention. Read more..

TOPICS:

FDA Accepts Otonomy's NDA for Middle Ear Effusion

April 29, 2015 12:27 pm | News | Comments

​Otonomy, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that its New Drug Application (NDA) for the approval of AuriProTM. Read more...

TOPICS:
Advertisement

Your Brain on Drugs: Functional Differences in Brain Communication in Cocaine Users

April 29, 2015 12:22 pm | by University of Texas Medical Branch | News | Comments

The brain function of people addicted to cocaine is different from that of people who are not addicted and often linked to highly impulsive behavior, according to a new scientific study. Read more...

TOPICS:

FDA Accepts BLA For Biogen, AbbVie MS Treatment

April 29, 2015 12:14 pm | News | Comments

Today Biogen and AbbVie announced that the U.S. Food and Drug Administration (FDA) has accepted for review the companies’ Biologics License Application (BLA) requesting marketing approval of ZINBRYTA (daclizumab high-yield process) for relapsing forms of multiple sclerosis (MS). Read more...

TOPICS:

FDA to Review Amgen's High Cholesterol Drug

April 29, 2015 11:58 am | News | Comments

Amgen announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) will review data supporting the Company's Biologics License Application (BLA) for RepathaTM (evolocumab) for the treatment of high cholesterol at a meeting on June 10, 2015. Read more...

TOPICS:

Breaking Ground on Biologics

April 29, 2015 11:01 am | by Ryan Bushey, Associate Editor | Articles | Comments

One of the final sessions for the 2015 Experimental Biology Conference in Boston, Massachusetts was on biologics. Over the course of two and a half hours, a panel of scientists and experts discussed their research and where they see opportunity in this field. Read more...

TOPICS:

3 Ways Technology is Changing the Face of Drug Discovery & Development

April 29, 2015 9:04 am | by Merrilyn Datta, PhD, President and General Manager, Definiens | Articles | Comments

While personalized medicine has been a goal for some time, there have been several obstacles. Although there has been an explosion in genomic data, the corresponding clinical utility for this data has been slow to be validated. Read more...

TOPICS:
Advertisement

World Malaria Day Brings Scourge into Spotlight

April 29, 2015 8:35 am | by Seth Augenstein, Digital Reporter | News | Comments

Malaria kills more than half a million people each year worldwide – and that’s after dramatic declines over the last decade. Read more...

TOPICS:

Takeda Agrees to Pay $2.4B in Diabetes Drug Suit

April 29, 2015 8:26 am | by Mari Yamaguchi, Associated Press | News | Comments

Takeda has faced product liability lawsuits in the U.S. involving about 9,000 people who say the company failed to inform them of the drug's cancer risks. Read more...

TOPICS:

OncoGenex Regains Right to Custirsen from Teva

April 29, 2015 8:22 am | News | Comments

This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva. Read more...

TOPICS:

Action Against Antibiotic Resistance Begins with Community

April 28, 2015 4:43 pm | by Wellcome Sanger Institute | News | Comments

To combat antibiotic resistance, scientists need to understand the evolution of bacteria and examine this alongside the characteristics of the populations they infect. Read more...

TOPICS:

Novartis Announces Phase 3 Study of CLL Drug Met Primary Endpoint

April 28, 2015 4:34 pm | News | Comments

The safety profile observed in this trial is consistent with other trials of Arzerra and no new safety signals were observed. Read more....

TOPICS:

U.N. Says It Will Try to Identify All Ebola Cases by June

April 28, 2015 4:21 pm | by Maria Cheng, AP Medical Writer | News | Comments

The World Health Organization said it aims to identify and isolate all new Ebola cases in West Africa by the end of May to stop the spread of the lethal virus before the rainy season. Read more...

TOPICS:

Scientists Uncover Surprising New Details of Potential Alzheimer’s Treatment

April 28, 2015 1:26 pm | by The Scripps Research Institute | News | Comments

Taking a new approach, scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered some surprising details of a group of compounds that have shown significant potential in stimulating the growth of brain cells and memory restoration in animal models that mimic Alzheimer’s disease. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading